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ABSTRACT
Aim: To evaluate the efficacy and safety of triple therapy
consisting single-session photodynamic therapy (PDT),
intravitreal bevacizumab (IVB) and intravitreal triamcino-
lone (IVTA) for treatment of neovascular age-related
macular degeneration (AMD)
Methods: Consecutive patients with subfoveal choroidal
neovascularisation (CNV) secondary to AMD were treated
with PDT using a standard protocol immediately followed
by 1.25 mg of IVB and 4 mg of IVTA. 1.25 mg of IVB was
given at 3 months for residual leakage. Best-corrected
Snellen visual acuity (BCVA) and fluorescein angiography
(FA) were performed prior to treatment. BCVA, intraocular
pressure (IOP) and presence of vitritis were documented
at 1 and 6 weeks, 3 and 6 months. FA was repeated at 3
and 6 months. Outcome measures included visual
improvement measured by logMAR equivalent, angio-
graphic evident of leakage and safety profile.
Results: 36 eyes of 33 patients, aged 76.4 (SD
10.5) years with mean follow-up of 14.7 (6.9–
19.2) months were analysed. Baseline logMAR acuity
was 1.22 (0.71). The mean logMAR acuity was 1.14
(0.62) and 1.18 (0.63) at 3 and 6 months respectively. At
6 months, 61.1% (22/36) showed stable or gaining vision,
and 27.8% (10/36) gained three or more lines. Twenty-
eight eyes (77.8%) achieved CNV resolution by single
session of triple therapy. One eye lost more than six lines
due to retinal pigment epithelium rip, three eyes showed a
significant cataract requiring surgery, and two showed
persistent raised IOP at 6 months. None resulted in
endophthalmitis or reported thromboembolic event.
Conclusions: Short-term results of single session triple
therapy suggested that it might be a useful treatment
option for neovascular AMD based on its low retreatment
rates, sustainable CNV eradication result and visual gain
achievement. However, the risk and benefits of using
intravitreal triamcinolone in addition to combined PDT and
IVB warrant further evaluation.
Age-related macular degeneration (AMD) is one of
the leading causes of blindness in the developed
world. It can be classified into non-neovascular
(dry) and neovascular (wet) form. The neovascular
form of AMD is characterised by the development
of choroidal neovascularisation (CNV). It contrib-
uted to a minority of cases, approximately 10% to
20% but associated with 80% to 90% of visual loss.
1
It is clear that no single therapy addresses the
multifactorial pathogenesis of the disease. In CNV,
tissue ischaemia and/or inflammation from age-
related changes triggers angiogenic signal molecules
such as vascular endothelial growth factor (VEGF).
Thus, the ideal therapeutic goal should achieve not
only CNV eradication but also inflammation
reduction and VEGF downregulation in order to
produce sustainable effect.
Photodynamic therapy (PDT) with verteporfin
works with its selective angio-occlusive effect. Its
effectiveness varies among different types of CNV.
According to the Treatment of Age-Related
Macular Degeneration with Photodynamic
Therapy study, it is most effective in predomi-
nantly classic type of CNV (at least half of the
lesion is classic) in reducing the risk of visual loss.
23
In the Verteporfin in Photodynamic therapy report
study, small, active, minimally classic or occult
CNV lesions may also respond.
2–4 However, PDT
monotherapy mainly achieves visual stabilisation
rather than visual improvement.
235Another draw-
back of PDT is the need for repeated treatments
resulting from the high recurrence rate of CNV,
23
which compromises the success of the therapy.
Subsequently, anti-inflammatory agents, like
intravitreal triamicinolone, have been introduced as
an adjunct for PDT to limit further VEGF upregula-
tion initiated by the therapy. This combination
therapy has shown to be beneficial when compared
with PDT monotherapy
6–9 in terms of functional
results and an extended treatment durability.
10 11
Antivascular endothelial growth factor (anti-
VEGF), on the other hand, functions by blockade
of VEGF-A, which is overexpressed in the process of
the disease. There are a few commercially available
anti-VEGF. Bevacizumab (Avastin) is a full-length
anti-VEGF antibody which is approved for intrave-
nous use in metastatic colon cancer.
12 13 Off-label
intravitreal use has been shown to be effective in
treating neovascular AMD.
14 Ranibizumab
(Lucentis) is an anti-VEGF fragment that binds all
isoforms of VEGF-A.
12 Pegaptanib sodium
(Macugen), the first FDA approved anti-VEGF for
intravitreal use, is an RNA aptamer that binds only
VEGF-A isoform 165. Studies have shown enlighten-
ing results in achieving visual gain, including
minimally classic or occult without classic neovas-
cular AMD, which traditionally might not respond
well to PDT.
15 However, the action of anti-VEGF
therapies seems to be transient. It inhibits continued
neovascularisation but does not destroy existing
CNV. As frequent retreatment is needed, this
inevitably exposes patients to repeated risks of
intravitreal injection, namely endophthalmitis and
posterior segment complications.
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of these agents. Combination use of PDT and anti-VEGF has
been shown to be superior to using either agent alone.
16 17 The
purpose of this case series is to study the effectiveness of single
session of triple therapy, namely photodynamic therapy,
intravitreal injection of bevacizumab(avastin) and triamcino-
lone in management of neovascular AMD. We mainly focus on
the anatomical, functional outcome and safety profile of single
session of this therapy.
METHODS
Consecutive cases of subfoveal choroidal neovascular (CNV)
due to age-related macular degeneration were recruited from 19
December 2005 to 5 February 2007. Patients with fluorescent-
angiography-diagnosed active subfoveal CNV due to age-related
macular degeneration with minimum follow-up of 6 months
were included. Patients with coexist pathology causing sub-
foveal choroidal neovascular such as myopic CNV, retinal
angiomatosis proliferation, intraocular surgery performed dur-
ing the study period or history of thromboembolic event were
excluded.
Complete ophthalmic examinations including best-corrected
Snellen visual acuity and intraocular pressure were recorded,
and fluorescent angiography was performed in the first visit.
Patients were then given photodynamic therapy with vertepor-
fin using standard protocol (6 mg/m
2, 50 J/cm
2, 600 mW/cm
2,
83 s), followed by intravitreal injection of 1.25 mg of bevacizu-
mab (Avastin, Genentech) in 0.05 ml and 4 mg of filtered
triamcinolone (Kenacort A, Bristol- Myers Squibb (HK)) in
0.1 ml within 1 h of PDT under aseptic conditions with
paracentesis performed at the same time.
Patients were followed up 1 week, 6 weeks, 3 months and
6 months after treatment. Best-corrected Snellen visual acuity,
intraocular pressure and presence of vitritis were recorded in
every visit. Fluorescent angiographies were repeated at 3 and
6 months. Intravitreal bevacizumab (1.25 mg) was injected if
fluorescent angiography showed features of persistent choroidal
neovascularisation at 3 months. The above procedures and
examinations were performed by a single surgeon in a single
centre after informed consent.
A paired t test was used to compare findings before and after
treatment. The Snellen visual acuity measured was converted to
logMAR equivalent for statistical analysis.
RESULTS
A total of 36 eyes of 36 patients were included in the analyses.
The mean age was 76.4 years old; 66% were male. Right and left
eye involvement was similar. Baseline lesions were 19.5%, 55.5%
and 25% for predominantly classic, pure occult and minimally
classic respectively; 58.3% were treatment-naive. The baseline
logMAR visual acuity was 1.22, and the mean follow-up time
was 14.7 months (table 1).
The outcome analysis focused on functional outcome,
anatomical outcome and evaluation of the safety of treatment.
Functional outcome was defined as the change in visual
acuity from baseline using logMAR equivalent. After a single
session of triple therapy, 66.7% and 61.1% achieved stable or
gaining vision 3 and 6 months, respectively. However, the
percentage with loss of six or more lines was 5.6% at 3 months,
which increased to 13.9% at 6 months (table 2). Longitudinal
analysis suggested a trend of visual improvement with a
maximum effect at 3 months (p=0.323) (fig 1). A subgroup
analysis for the naive group versus the pretreatment group
suggested insignificant results.
Anatomical outcome was defined as complete resolution of
angiographic evidence of CNV. After a single session of triple
therapy, 28 of 36 eyes (77.8%) achieved angiographic resolution.
There were persistent CNV in eight of 36 eyes (22.2%). The
percentage of anatomical outcome was the same at 3 and
6 months.
Regarding treatment safety, three (8.3%) had a significant
cataract requiring surgery, and one (2.8%) lost more than six
lines due to retinal pigment epithelium rip. None had pigment
epithelial detachment. There were nine (25%) cases observed
with mild vitritis in the first 6 weeks, but all subsided
spontaneously. There were one transient ocular hypertension
in the first week and four at 6 weeks, all resolving with topical
medication. There were two cases encountered with persistent
elevated intraocular pressure requiring treatment for 6 months.
Neither endophthalmitis nor a thrombo-embolic event was
reported in this series.
Figure 2 shows fundus and FA images of a case receiving triple
therapy. On presentation (fig 2A, B), the left-eye visual acuity
was 0.5, and FA showed occult CNV. At month 3 after
treatment (fig 2C, D), the VA improved to 0.8, and CNV dried
up. Results were sustained at month 6. This case illustrated
successful eradication of CNV by a single session of triple
therapy.
Figure 3 shows fundus and FA images of another case
receiving triple therapy with supplementary bevacizumab at
month 3. On presentation (fig 3A–C), the right-eye visual acuity
was 0.2. FA showed large occult CNV with late leakage. At
month 3 (fig 3D–F), VA was 0.05, and evidence of persistent
angiographic leakage was found. Intravitreal bevacizumab
(fig 3G) was given, and FA repeated at month 6 showed a
significant reduction in angiographic leakage. The VA improved
to 0.16, and the size of the scotoma was reduced. Although this
case did not achieve CNV eradication, visual function was
improved. This illustrated the beneficial effect of triple therapy
in reducing the area and extent of leakage.
Table 1 Demographics of patients included in the study
Mean age in years (SD), range 76.4 (10.5), 52 to 92
Gender (n) Male: 24; female: 12
Laterality (n) Right: 19; left: 17
Prior treatment (n) Naı ¨ve: 21; past treatment: 15
Baseline lesion types (n) Predominantly classic: 7 (19.5%)
Pure occult: 20 (55.5%)
Minimally classic: 9 (25%)
Mean (SD) follow-up, range 14.7 (2.9), 6.9 to 19.2 months
Table 2 Visual acuity distribution after single session of triple therapy
for neovascular age-related macular degeneration
LogMAR best-corrected visual acuity 3 months (%) (n) 6 months (%) (n)
Gaining vision 52.7 (19/36) 41.7 (15/36)
>3 lines 30.5 (11/36) 27.8 (10/36)
,3 lines 22.2 (8/36) 13.8 (5/36)
Stable vision 13.8 (5/36) 19.4 (7/36)
Losing vision
,3 lines 8.3 (3/36) 13.9 (5/36)
>3t o,6 lines 13.9 (5/36) 8.3 (3/36)
>6 lines 11.1 (4/36) 16.7 (6/36)
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Our study showed that a single session of triple therapy using a
standard protocol of PDT by verteporfin, intravitreal bevacizu-
mab and triamcinolone in treating neovascular AMD yielded
encouraging results. In our series, 78% achieved CNV eradica-
tion, and 61% achieved visual stabilisation at 6 months, with
30% and 28% gaining three or more lines at 3 and 6 months
respectively. Successful CNV eradication at 3 months remained
so for 6 months. Therefore, a single session of triple therapy is
indeed time-saving with sustainable effects.
In a randomised controlled study performed in Vienna,
Austria comparing 1 mg of intravitreal bevacizumab with the
combination of standard PDT by verteporfin and 4 mg of IVTA
for neovascular AMD, the use of intravitreal bevacizumab alone
appears to result in significantly better visual outcomes.
18
However, at 3 and 6 months, 50% and 43% required retreat-
ment in the bevacizumab group, while 79% and 14% required
retreatment in the combination group. This finding supported
the fact that PDT plus IVTA achieved better results in CNV
eradication at 6 months, but the functional outcome is less
promising when compared with intravitreal bevacizumab. In
our single-session triple therapy, only 22% and 22% required
retreatment at 3 and 6 months respectively. Therefore, triple
therapy may have a role in reducing the retreatment rate while
preserving the functional benefit of bevacizumab.
Other regimens of triple therapy in neovascular AMD are
recently published, and they all showed a significant functional
improvement. In the series by Augustin et al which included 104
eyes, reduced light dose of PDT by verteporfin, 800 mgo f
dexamethasone and 1.5 mg of bevacizumab intravitreal injec-
tion were used.
19 After one cycle of treatment, the mean visual
acuity was significantly improved by 1.8 lines, with 39.4%
gaining three or more lines and 3.8% losing three or more lines.
In another series by Ahmadieh et al, which included 17 eyes, a
standard PDT protocol, 1.25 mg of bevacizumab and 2 mg of
triamcinolone intravitreal injection, was used.
20 The mean
pretreatment BCVA was 0.74 (0.33) (logMAR) which was
significantly improved to 0.52 (0.36) at 3 months. Our triple
therapy series demonstrated a trend of visual improvement with
a mean of 0.78 lines at 3 months. However, the functional
improvement is less obvious at 6 months. Possible reasons
included:
c The use of 4 mg IVTA. The higher dosage of IVTA increases
the risk of side effect, mainly cataract, vitritis and ocular
hypertension. These accounted for the proportion of visual
lost in our series.
c Eyes that were previously treated by PDT were not
excluded. As multiple PDT regimens may have an adverse
effect on physiological choroids, RPE and even neurosensory
Figure 1 Change in best-corrected visual acuity form baseline to
6 months follow-up after triple therapy. The grey squares joined together
with lines show the means. Error bars show the 95% CI of the mean.
Figure 2 Fundus and fluorescein angiography images of a case receiving triple therapy.
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21 22 visual improvement may be underestimated or
even limited by our suggested triple therapy.
In contrast, in the series by Ahmadieh et al, 58.8%, versus 22%
in our series, required a second injection at 3 months. This may
be attributed to our higher dosage of IVTA used. The latter
questions will remain to be investigated by further comparative
studies with adjusted dosage of IVTA.
A single session of triple therapy, therefore, has its potential
advantages. It reduces the risk of multiple PDT, which may
induce CNV recurrence by aggravation of choroidal ischaemia
and subsequent overexpression of VEGF.
23 Triamcinolone has
been shown to suppress the early proangiogenic response in RPE
cells after PDT in vitro
24 and itself affects CNV independently.
25
Intravitreal bevacizumab can work synergistically with PDT
against any existing CNV and also counteract the adverse effect
of PDT. Thus, triple therapy saves treatment costs, consultation
time and unnecessary multiple intravitreal injections.
Since the era of PDT, plenty of articles have been published
on the combined use of PDT with intravitreal triamcinolone.
Our trial was aimed at studying the additional effect of an extra
agent, bevacizumab, in managing neovascular AMD. It is not
until recently, in 2007, another regimen of triple therapy, that
replacing triamcinolone by dexamethasone has been advo-
cated.
19 It is believed that the shorter half life of dexamethasone
with its additional antifibrotic, antiproliferative and antimigra-
tion properties can result in a better efficacy with fewer side
effects than with triamcinolone. However, there are few
published papers on the use of combined PDT with dexametha-
sone before and during our study. We believe that the use of
dexamethasone may result in fewer side effects, mainly raising
intraocular pressure; however, its efficacy may need to be
proven by a larger trial.
Our study is not without its limitations. Supplementary
information of retinal thickness would be useful to show the
extent and effect of therapy in the reduction of macular
oedema. The number of CNV subtypes and previously treated
group versus non-treated eyes were too small for a meaningful
subgroup analysis. The intrinsic limitation of case series
precluded statistically significant results, so only a trend of
visual improvement was shown in the results of functional
outcome. Therefore, a larger-scale comparative study with
optical coherent tomography findings and use of different doses
and types of anti-inflammatory or antiangiogenic agents would
be helpful to provide further information on the best treatment
regimen for neovascular CNV in age-related macular degenera-
tion.
CONCLUSION
Short-term results of single-session triple therapy suggest that it
might be a useful treatment option for neovascular AMD based
on its low retreatment rates, sustainable CNV eradication result
and visual-gain achievement. However, the risks and benefits of
using intravitreal triamcinolone, in comparison with other anti-
inflammatory agents, in triple therapy warrant further evalua-
tion.
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